Prm272 - The Eunethta Transferability Tool: Application to Novel Treatments for Relapsed Refractory Multiple Myeloma in the Irish Healthcare Setting

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2911
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Carfilzomib for Relapsed or Refractory Multiple Myeloma

The Lancet Oncology
Oncology
2018English

Prm46 - Measuring and Analysing the Maturity of Overall Survival Data for Treatments for Relapsed or Refractory Multiple Myeloma

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Methodology of a Novel Risk Stratification Algorithm for Patients With Multiple Myeloma in the Relapsed Setting

Oncology and Therapy
Oncology
2019English

Bendamustine in Patients With Relapsed or Refractory Multiple Myeloma

European Journal of Medical Research
Medicine
2010English

Nuclear Medicine Imaging of Multiple Myeloma, Particularly in the Relapsed Setting

European Journal of Nuclear Medicine and Molecular Imaging
MedicineNuclear MedicineRadiologyImaging
2016English

Letter: Quest for the Best in Relapsed/Refractory Multiple Myeloma: A Mis-Placed ENDEAVOR

Clinical Therapeutics
Pharmacology
2019English

Bendamustine, Pomalidomide, and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma

Blood Cancer Journal
OncologyHematology
2018English

Correction: Management of Relapsed and Refractory Multiple Myeloma: Novel Agents, Antibodies, Immunotherapies and Beyond

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2019English

Psy63 - Cost by Outcomes Analysis of Novel Triple-Combination Therapies for Relapsed/Refractory Multiple Myeloma in Brazil

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy